COVID-19: update in innovazione, ricerca e sviluppo


  • Francesco Burrai Incaricato Progetti di Ricerca, SC Formazione, Ricerca e Cambiamento Organizzativo, ATS Sardegna, Sassari - Italia
  • Luigi Apuzzo Cardiologia d’emergenza con UTIC, AORN Caserta - Italia
  • Valentina Micheluzzi Cardiochirurgia, AOU di Sassari, Sassari - Italia


Parole chiave:

COVID-19, Innovation, Pharma, Research, SARS-COV-2


Following the pandemic state, produced by the infection with the new coronavirus SARS-CoV-2, and the consequent state of health emergency, it is considered scientifically important to propose an update on ongoing clinical pharmacological trials, the most advanced international projects in the innovation sector and the most important statistical mathematical approaches to use a model for predictive purposes. In Italy there are several experimental molecules subjected to rigorous RCT studies approved by AIFA. In the Research & Development sector, the CERN in Geneve with the “CERN against COVID-19 project” represents the most advanced innovation, while in predictive statistical techniques, the mathematical model with wavelet approach allows to predict variables such as the persistence of the virus or to calculate the probability of transmission, strategic information for health planning.

Riferimenti bibliografici

Center for Disease Control and Prevention. Situation Summary. Centre for Disease Control and Prevention. 2020. (Data ultimo accesso: 2/3/2020).

World Health Organization. WHO Director-General’s opening remarks at the media briefing on COVID-19. 11 march 2020. (Data ultimo accesso: 29/3 2020).

World Health Organization. Coronavirus disease 2019 (COVID-19) Situation Report – 67. 2020. (Data ultimo accesso: 2/5/2020).

World Health Organization. Global surveillance for COVID-19 caused by human infection with COVID-19 virus. 2020. (Data ultimo accesso: 20/3/2020).

Ministero della Salute. Circolare n. 6360 del 27/02/2020 “COVID-19”. Aggiornamento.

National Health Institute. NIH clinical trial of remdesivir to treat COVID-19 begins. 2020. (Data ultimo accesso: 29/3/2020).

Sheahan TP, Sims AC, Leist SR, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020;11:222. (Data ultimo accesso: 2/5/2020).

Cao B, Wang Y, Wen D, et al. A Trial of Lopinavir Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020;382:1787-99. doi: 10.1056/NEJMoa2001282.

Baden LR, Rubin EJ. Covid-19-The Search for Effective Therapy. N Engl J Med. 2020; 382:1851-2. doi: 10.1056/NEJMe2005477.

Decreto Legge 17 marzo 2020, n. 18.

Agenzia Italiana del Farmaco. Sperimentazioni cliniche – COVID-19. Agenzia Italiana del Farmaco. 2020. (Data ultimo accesso: 2/5/2020).

Krantz SG, Srinivasa Rao ASR. Level of underreporting including underdiagnosis before the first peak of COVID-19 in various countries: Preliminary retrospective results based on wavelets and deterministic modeling. Infection Control & Hospital Epidemiology. 2020;41:857-9. doi: 10.1017/ice.2020.116.




Come citare

Burrai F, Apuzzo L, Micheluzzi V. COVID-19: update in innovazione, ricerca e sviluppo. G Clin Nefrol Dial [Internet]. 1 agosto 2020 [citato 22 settembre 2021];32(1):111-23. Available at:

Puoi leggere altri articoli dello stesso autore/i

1 2 > >>